Miguel Martín

Featured in: Favicon

Articles

21 Ribociclib (RIB) + Nonsteroidal Aromatase Inhibitor (NSAI) as Adjuvant Treatment in Patients (pts) With HR+/HER2- Early Breast Cancer (EBC): Final Invasive Disease-Free Survival (iDFS) Analysis From the NATALEE Trial

Aug 7, 2024 | cancernetwork.com | Chiun-Sheng Huang |Miguel Cabral Martin |Miguel Martín |Sherene Loi |Michael Untch

BackgroundInterim results from the phase 3 NATALEE trial showed that ribociclib added to standard-of-care adjuvant nonsteroidal aromatase inhibitor (NSAI) had a significant invasive disease-free survival (iDFS) benefit in patients with stage II/III HR+/HER2- early breast cancer (EBC) at risk of recurrence, including those with node-negative disease. We present the final protocol-specified analysis of iDFS (primary end point).
Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study - npj Breast Cancer

Apr 25, 2024 | nature.com | Matthew Goetz |Sara M. Tolaney |Valentina Guarneri |Miguel Cabral Martin |Miguel Martín |Nadia Harbeck | +1 more

AbstractIn monarchE, adjuvant abemaciclib significantly improved invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS), with sustained benefit beyond the 2-year treatment period. Abemaciclib dose reductions were allowed to proactively manage adverse events. Exploratory analyses to investigate the impact of dose reductions on efficacy were conducted.

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.